All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by GSK, Novartis, AOP, Sobi and Takeda and supported through independent educational grants from Bristol Myers Squibb, Blueprint Medicines, Incyte and Merck Sharp & Dohme LLC, Rahway, NJ, USA. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View MPN content recommended for you
EBMT 2023
22 May 2023
Find out here 👉 https://t.co/5WGVb7qxNY
@NicoGagelmann #MPN #MPNsm #MF
2 May 2023
We asked, Is transplantation still the only curative treatment for #MF?
Find out here: https://t.co/HDSOjJzFws
#mpnsm #mpn
25 Apr 2023
25 Apr 2023
24 Apr 2023
Juan Carlos Hernández Boluda of @GVAclinic talks about selecting the best conditioning regimen & #GvHD prophylaxis in allo-HCT for #myelofibrosis. FluBu may be considered the standard conditioning regimen for both RIC and MAC in #MPN
#mpnsm #medicalcongress
24 Apr 2023
@jjkiladjian @HopSaintLouis discusses if HSCT is still the only curative option for #MPN. He emphasizes on combination therapy considering disease complexity, clonal architecture & limitations of currently available drugs
#mpnsm @Institut_IRSL @Institut_cancer
<span> </span>
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Do you include basal serum tryptase (bST) testing in the diagnostic evaluation of patients with MPN?